The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism
- 1 April 1996
- journal article
- case report
- Published by Springer Nature in Intensive Care Medicine
- Vol. 22 (4) , 353-355
- https://doi.org/10.1007/bf01700458
Abstract
To describe the use of inhaled aerosolized prostacyclin (IAP) in a patient with life-threatening pulmonary hypertension secondary to pulmonary embolism and to discuss the possible use of inhaled prostacyclin in the management of pulmonary embolism. Case report. Intensive care unit of a university teaching hospital. One patient with severe pulmonary hypertension secondary to acute-on-chronic pulmonary embolism. Conventional medical management of massive pulmonary embolism and inhaled aerosolized prostacyclin (IAP). Description of clinical course, haemodynamic data and gas exchange data. We describe a patient with massive pulmonary embolism for whom the addition of IAP to his therapy appeared to result in a transient improvement in pulmonary haemodynamics and gas exchange.Keywords
This publication has 6 references indexed in Scilit:
- Aerosolised prostacyclin in adult respiratory distress syndromeThe Lancet, 1993
- PGI2 Aerosol versus Nitric Oxide for Selective Pulmonary Vasodilation in Hypoxic Pulmonary VasoconstrictionEuropean Surgical Research, 1993
- Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.Circulation, 1991
- Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)Annals of Internal Medicine, 1990
- Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).Heart, 1987
- The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary diseaseThe American Journal of Cardiology, 1971